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ABSTRACT 
Objectives: Periodic fever syndromes (PFS) are characterised by recurrent attacks of fever and 
localised inflammation. This study examined the diagnostic pathway and treatments at tertiary 
centres for FMF, TRAPS and MKD/HIDS. 
Methods: PFS specialists at medical centres in the USA, European Union and Eastern 
Mediterranean participated in a retrospective chart review, providing de-identified data in an 
electronic case report form. Patients were treated between 2008-2012 with at least 1 year of 
follow-up, all had clinical and/or genetically proven disease, and were on/eligible for biologic 
treatment.  
Results: 134 patients were analysed in total: FMF (n=49), TRAPS (n=47), and MKD/HIDS 
(n=38). Fever was commonly reported as severe across all indications. Other frequent severe 
symptoms were serositis for FMF patients and elevated acute-phase reactants and gastro-
intestinal upset for TRAPS and MKD/HIDS. A long delay from disease onset to diagnosis was 
seen within TRAPS and MKD/HIDS (5.8 years and 7.1 years, respectively) with a 1.8 year delay 
in FMF. An equal proportion of TRAPS patients first received anti-IL-1 and anti-TNF biologics 
whereas IL-1 blockade was the main choice for MKD/HIDS and FMF patients. For TRAPS 
patients, treatment with anakinra versus anti-TNF treatments as first biologic resulted in 
significantly higher clinical and biochemical responses (p=0.03 and p<0.01, respectively). No 
significant differences in responses were observed between biological agents among other 
cohorts.  
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Conclusions: Referral patterns and diagnostic delays highlight the need for greater awareness 
and improved diagnostics for PFSs. This real-world treatment assessment supports the need for 
further refinement of treatment practices.  
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Significance and Innovations 
• This study is one of the largest retrospective analyses of biological eligible/currently 
treated patients with the periodic fever syndromes of FMF, TRAPS and MKD/HIDS in 
geographic scope, patient recruitment and medical centre participation 
• A long delay from disease onset to diagnosis was seen within TRAPS and MKD/HIDS 
(5.8 years and 7.1 years, respectively) with a 1.8-year delay in FMF 
• An equal proportion of TRAPS patients first received anti-IL-1 and anti-TNF biologics 
whereas IL-1 blockade was the main choice for MKD/HIDS and FMF patients 
• For TRAPS patients, treatment with anakinra versus anti-TNF treatments as first biologic 
resulted in significantly higher clinical and biochemical responses (p=0.03 and p<0.01, 
respectively). Therefore, the authors would recommend use of IL-1 inhibition over TNF 
inhibition in TRAPS patients as first biologic agent based on findings from this study and 
other existing literature. No significant differences in responses were observed between 
biological agents among other cohorts 
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INTRODUCTION 
Periodic fever syndromes (PFS) are characterised by attacks of clinical and biochemical 
inflammation. They are often associated with genetic defects in the innate immune system and a 
chronic disease course; the patients may suffer from the sequelae of persistent inflammation.
[1, 2]
 
The three best known PFSs are the scope of the present study: Familial Mediterranean Fever 
(FMF), Tumour necrosis factor receptor-associated periodic syndrome (TRAPS) and Mevalonate 
Kinase Deficiency (MKD) associated periodic syndrome, also known as hyper-
immunoglobulinemia D syndrome (HIDS). Although they have different clinical features and 
etiology, all three are characterised by intermittent attacks, fever and high acute phase 
reactants.
[3]
 With the exception of the eastern Mediterranean, each has a very low prevalence
[4, 5]
 
and thus are considered rare diseases. Recent recommendations from Single Hub and Access 
point for paediatric Rheumatology in Europe (SHARE) have focused on the clinical management 
of TRAPS, MKD/HIDS and cryopyrin-associated periodic syndromes, but have referenced a 
lack of evidence of patient treatment experience and outcomes.
[6]
 This international study was 
designed to analyse real-life data to describe diagnostic pathway, referral to tertiary centres and 
subsequent treatment by specialists. 
METHODS 
Data source 
Medical centres in the USA, European Union (France, Germany, Italy, the Netherlands and the 
United Kingdom) and Eastern Mediterranean (Israel and Turkey) which specialised in treatment 
of PFS were invited to participate in this retrospective study. A uniform data set was collected 
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from the medical records of eligible subjects via case report forms. The study was granted 
Institutional Review Board (IRB)/ethical approval by the partnering institutions as needed and 
complied with International Ethical Guidelines for Biomedical Research Involving Human 
Subjects, Good Clinical Practice Guidelines, the Declaration of Helsinki, and local laws. Data 
collection followed data privacy regulations in each country. 
Subject inclusion criteria 
Subjects who met all the following inclusion criteria were considered for enrolment: 1) children 
or adults who have clinically and/or genetically confirmed diagnosis of FMF, TRAPS or 
MKD/HIDS; 2) were treated by a specialist physician for the relevant disease at any point during 
the period between 2008 and 2012 with a minimum length of follow up after diagnosis of 12 
months; and 3) are either eligible for or receiving treatment with a biologic therapy. 
Specific criteria defined inadequate disease control for FMF, TRAPS and MKD/HIDS thereby 
suggesting patients eligible for a biologic.  
For FMF, patients were required to have an inadequate response to colchicine, defined as either a 
minimum of one typical acute attack per month for at least three consecutive months or 
continued attacks in a patient compliant with or intolerant to effective doses of colchicine. For 
TRAPS, patients were required to show inadequate disease control with corticosteroids prior to 
receiving an effective biologic therapy, defined as more than six episodes per year or elevated C-
reactive protein (CRP) >10mg/L and/or serum amyloid A protein (SAA) >10 mg/L between 
attacks. Lastly, for MKD/HIDS, inadequate control referred to patients having a history of ≥3 
febrile acute flares in a 6-month period when not receiving prophylaxis treatment with a duration 
of each flare ≥4 days and limitation of normal daily activities or elevated CRP >10mg/L and/or 
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SAA >10 mg/L in between attacks. On-treatment efficacy and duration data was not collected for 
patients enrolled into an interventional clinical study or following initiation of canakinumab 
treatment to avoid any sponsor bias (the decision to initiate of canakinumab was however 
recorded). Therefore, treatment response analysis in this study does not include responses for 
patients treated with canakinumab. 
Outcomes 
Patient demographics, genetic data and clinical characteristics at disease onset, diagnosis, and 
during treatment were collected including treatment duration, reason for discontinuation, 
functional status improvement, clinical and biochemical response outcomes. Complete clinical 
response was defined by a normalisation of the associated disease-related symptoms, whereas 
biological control referred to normal levels of CRP / SAA (median <10mg/L). 
Statistical analyses 
Patient characteristics and treatment information were analysed descriptively. Chi-square test for 
independence was used to assess differences between best clinical and biochemical response 
rates between biologic agents. All analyses were conducted using IBM SPSS Statistics 19 (IBM 
Corp. Released 2010. IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY: IBM 
Corp). 
RESULTS 
Physicians from 16 medical centres extracted information on 134 patients: FMF (n=49), TRAPS 
(n=47), and MKD/HIDS (n=38; see Supplemental Table S1 for country breakdown). Post-hoc, 
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five FMF patients were excluded because they lacked two pathogenic mutations (they were 
R202Q heterozygous, K695R heterozygous and E148Q homozygous). 
Six TRAPS patients with the R92Q mutation were analysed separately due to previously 
reported differences in phenotype (Table 1).
[7]
  
FMF 
The median age of disease onset and diagnosis of these biological eligible/treated FMF patients 
was 2.0 and 4.9 years, respectively with a median delay in diagnosis of 1.9 years. Fever and 
arthritic flares occurred at a median frequency of 26.0 and 12.0 times per year, respectively, with 
a duration of 3.0 days per attack. The majority (53%) of patients experienced severe serositis 
(Table 1). 
Of the 49 patients with FMF included in the analysis, 73% were less than 18 years old when first 
seen by a specialist. Regardless of age, the majority saw between 1-2 physicians prior to 
diagnosis (83% and 62% for children and adults, respectively). The children were primarily 
diagnosed by paediatricians whereas adults were mostly seen by general practitioners. The 
referring physician diagnosis was mostly accurate, with 52% of children and 75% of adults 
correctly diagnosed with FMF by the referring physician (Table 2). 
Of the 27 FMF patients exposed to biologic therapy, 82% were provided an anti-IL-1 agent, 
either anakinra (14) or canakinumab (8), as the first biologic. Complete clinical response of 
patients treated with anakinra was achieved in 7 out of 14 cases whereas biological control was 
achieved in 6 out of 14 cases reviewed. The remaining patients received either an anti-TNF 
(etanercept or adalimumab; 4) or interferon alpha (1). 25% of patients who received a non-IL-1 
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biologic had complete clinical and biological control, although the difference compared to the 
anti-IL-1 anakinra treated group was not statistically significant (p = 0.79 and p = 0.42). Overall, 
the mean duration of therapy for anti-IL-1 was 9.7 months compared to 9.3 and 17.0 months for 
anti-TNF and interferon alpha therapy (Table 3, Table 4).  
Lack of efficacy was the reason for discontinuation for all 3 patients on anti-TNF therapy and 1 
patient on interferon therapy. Of the 10 patients discontinuing anakinra treatment, the main 
reasons cited were side effects (5) and lack of efficacy (4), of which 1 patient experienced both.  
TRAPS 
Of the 47 TRAPS patients included in the chart review, six patients had the low penetrance 
R92Q mutation, while the remaining 41 had other mutations. For the TRAPS R92Q cohort, the 
median age of disease onset and diagnosis was 10.4 and 10.9 years, respectively, with a delay in 
diagnosis of 1.4 years. The TRAPS non-R92Q group (furthermore referred to as TRAPS) had 
medians of 7.4, 27.6 and 5.8 for the respective characteristics.  
The age of patients at time of data collection was broadly similar for both TRAPS cohorts, 
although children accounted for 67% of TRAPS R92Q and 41% of non-R92Q mutations. 
Differences existed in physicians seen across cohorts and age ranges, with TRAPS R92Q 
children mostly seeing 3-4 physicians prior to diagnosis (3 of 4). For the TRAPS cohort, 65% of 
children saw 1-2 physicians and 46% of adults saw 3-4 pre-diagnosis. The referring physician of 
children was a paediatrician in 2 of 4 and 10 of 17 (59%) cases for the R92Q and TRAPS 
population respectively. In the majority of cases, no diagnosis was provided by the referring 
physician (Table 2). 
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In the TRAPS R92Q cohort, 4 patients were exposed to etanercept as the first biologic agent, and 
2 received anakinra. Complete clinical and biochemical responses were achieved in 1 in 4 (25%) 
etanercept patients and 1 of 2 (50%) anakinra patients (Table 3). 
Of the 41 TRAPS patients, approximately half of the patients were treated with etanercept as first 
biologic (54%) with the remaining patients being treated with anakinra (41%) and canakinumab 
(5%). Patients were significantly more likely to have a complete clinical response (p = 0.03) and 
complete biochemical response (p < 0.01) on anakinra compared to anti-TNF. Patients requiring 
second-line therapy were exposed to anakinra (75%), canakinumab (17%) or adalimumab (8%). 
Third-line therapies were also focused on anti-IL-1 therapies (75%; Table 3, Table 4).  
13 TRAPS patients discontinued anti-TNF treatment, with 1 patient discontinuing both 
etanercept and adalimumab. Notably, 7 of 13 patients receiving etanercept discontinued due to 
lack of efficacy and 2 due to diminished symptoms. Only 6 TRAPS patients receiving anakinra 
discontinued this therapy with the main reasons being side effects (2) and enrolment in a clinical 
trial (2).  
MKD/HIDS 
MKD/HIDS patients had a median age of disease onset and diagnosis of 0.5 and 8.9 years, 
respectively with a median delay in diagnosis of 7.1 years. Fever and arthritic flares occurred at a 
median frequency of 12.0 and 12.5 times per year with a duration of 5.0 and 7.5 days per attack, 
respectively. The majority of patients experienced severe cases of fever (87%) or elevated acute 
phase reactants (79%), most of the time together (74%; Table 1). Over half of patients suffered 
from painful lymph nodes, loss of appetite, nausea, abdominal pain, diarrhoea and oral ulcers. 
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None of the more severe phenotypes involving neurological complications (and typically 
grouped under the diagnosis of mevalonic aciduria) were noted in this patient cohort. 
Of the 38 patients with MKD/HIDS, 66% were less than 18 years old when first seen by a 
specialist. Children were primarily seen by 1-2 physicians (76%) whereas adults mostly saw 
more than three physicians before diagnosis (92%). Similar to the other periodic fevers, children 
were generally referred by paediatricians (57%). Incorrect or no diagnosis was reported for 77% 
of children at the time of referral to a specialist, whereas adults were seen by a variety of 
specialties, none of whom produced a correct diagnosis (Table 2). 
For MKD/HIDS patients receiving biologic therapy, 71% received anti-IL-1 as a first agent, 68% 
being anakinra. Anti-TNF (etanercept) and anti-IL6 (tocilizumab) were given to 26% and 3% of 
patients, respectively. The differences in complete clinical response between anakinra and anti-
TNF (52% vs. 88%) did not reach statistical significance (p = 0.08 and p = 0.12 for clinical and 
biologic control, respectively). A similar non-significant difference was found for complete 
biochemical response (43% vs. 75% for anti-IL-1 and anti-TNF). Canakinumab was mainly used 
as a second biologic agent in 3 of 7 cases, with limited use of etanercept (2 of 7), anakinra (1 of 
7), and tocilizumab (1 of 7; Table 3, Table 4). 
15 patients discontinued biologic treatment. All 4 etanercept and 1 tocilizumab discontinuations 
were for lack of efficacy. Of the 10 anakinra patients stopping treatment, 5 were due to lack of 
efficacy and 3 because of patient’s wish/preference.  
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Mutations 
All patient cases in this study were diagnosed on clinical grounds. In addition, all patient cases in 
this study reported a mutation. At time of referral to a PFS specialist, 71% of FMF, 79% of 
TRAPS and 63% of MKD/HIDS patients underwent genetic testing. 
The majority of FMF patients (90%) had the M694V point-mutation in the MEFV gene, mostly 
homozygous in nature (84%; Supplemental Table S2). 
There was a greater variety of TRAPS mutations seen to the TNFRSF1A gene, with 17% 
involving cysteine mutations; 17% were T50M mutations (Supplemental Table S3). 
The majority of patients with MKD/HIDS (82%) carried the common V377I mutation, and were 
mostly compound heterozygous with a variety of other mutations (81%; Supplemental Table S4). 
DISCUSSION 
This study represents one of the largest retrospective analyses of biological eligible/currently 
treated patients with the periodic fever syndromes, FMF, TRAPS and MKD/HIDS in geographic 
scope, patient recruitment and medical centre participation. Participating physicians were 
internationally recognised specialists in treating these conditions. 
As expected, a high proportion of these biological eligible/treated patients across all three 
conditions presented at disease onset with severe fever symptoms. In addition, the FMF cohort 
had the highest rate of severe serositis (53%). In TRAPS and MKD/HIDS, elevated acute phase 
reactants and GI upset were the most common symptoms classed as severe. The likelihood of 
correct diagnosis and associated referral patterns were correlated with frequency of disease 
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incidence. A long delay from disease onset to diagnosis was seen within TRAPS and 
MKD/HIDS (5.8 years and 7.1 years, respectively) compared to 1.8 years in the FMF cohort. 
Treatment patterns largely followed previous guidelines. An approximately equal proportion of 
TRAPS patients received anti-IL-1 and anti-TNF biologics in first line whereas IL-1 blockade 
was the main choice for MKD/HIDS and FMF patients. 
FMF 
It should be underlined that the FMF patients analysed had unusually severe disease with an 
inadequate response to colchicine, and only represent a very small portion of the FMF 
population.
[8]
 Unfortunately no definition of colchicine-resistance/intolerance has been widely 
agreed upon.
[9-12]
 However, the definition for this study is in accordance with multiple papers 
that have specifically addressed this issue.
[13, 14]
 
In this study there were differences in referral to the specialist not only between adults and 
children but also compared to TRAPS and MKD/HIDS. The majority of the childhood FMF 
patients (83%) were seen only by 1-2 physicians before they were referred to a recognised 
expert. The percentage of patients seen by >3 physicians were much less in children than adults. 
This suggests that physicians treating difficult paediatric FMF refer more quickly to specialists 
than do physicians treating difficult FMF in adults. Alternatively, this might simply reflect that 
patients diagnosed in adulthood had lived long enough to have their diagnosis missed by multiple 
physicians. 
Furthermore, it is interesting to note that 15% of adult FMF patients were referred by a 
paediatrician. This reflects transition of patients from paediatricians upon reaching adulthood and 
the disease awareness among paediatricians and suggests they are likely refer the previously 
Page 15 of 33
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
   
15 
 
undiagnosed parents or older siblings to specialists as well. In this study a large portion of the 
FMF patients (65%) were from Turkey and Israel where the disease is frequent and well 
recognised.
[15-17]
 This may explain the moderately higher percentage of patients correctly 
diagnosed by referring physician between Turkey and Israel (56%) and Europe (40%). Although, 
it should be noted that there are regions in Europe where physicians have good awareness of 
FMF due to the higher numbers of residents with the relevant ethnic background.  
The majority of the FMF patients who had an inadequate response to colchicine went on to 
receive biologic treatments of which anti-IL-1 treatments were the most common and 50% of the 
patients responded to anti-IL-1 treatment. It is also noted that there are differences between the 
mean (9.3 months) and median (3.0 months) duration of anti-IL-1 therapies, suggesting specialist 
physicians may use these agents on demand or short-term for control. 
In the anti-TNF-treated FMF group (n=4), there was a 25% clinical and biologic response rate 
observed. However, this result should be interpreted with caution due to the limited patient 
numbers. Of these patients, two had sacroiliitis, with both experiencing at least a partial 
response, confirming that anti-TNF may be effective for this feature of the disease. 
TRAPS 
TRAPS is a rare disease whose diagnosis relies on a high index of suspicion, consequently there 
is a need for physician awareness.
[18, 19] 
In this study TRAPS patients saw more physicians before 
a correct diagnosis (median of 3.0) than FMF (median of 2.0) and are rarely diagnosed correctly 
before referral to a specialist. Inclusion of only six R92Q patients means interpretation is 
difficult, but we confirm previous published evidence that these patients have a similar 
phenotype as patients with other TNFRSF1A mutations but with shorter and more frequent 
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disease flares. Furthermore, the R92Q population had a shorter delay in diagnosis (5.8 years) and 
lower age at diagnosis (16.7 years); the reason for this is unclear; it may be an artefact of small 
patient numbers. R92Q TRAPS is less frequently associated with a family history so this is 
unlikely to reflect family screening. 
Of the TRAPS patients in this study who were not able to achieve control without biologic 
treatment, almost equal numbers received IL-1 targeting treatment and anti-TNF treatment as 
first-line biologic treatment. We observed a significantly better biologic and clinical response 
rate to anti-IL-1 treatment compared with anti-TNF agents. Of the 20 TRAPS patients receiving 
anti-TNF therapy as first choice biologic, 13 discontinued the anti-TNF, including 7 of 12 who at 
one point in their treatment had complete clinical control, and 5 of 8 who had complete 
biochemical control. Reasons for discontinuation of anti-TNF treatment range from apparent 
disease amelioration over time to lack of efficacy. It is noted that anti-TNF agents may be given 
as a monotherapy or with methotrexate in an effort to block antibody production and control 
symptoms in the longer term. However, the 65% discontinuation rate is consistent with a 
previous retrospective analysis of this patient population describing low and transient response 
rates in TRAPS patients treated with anti-TNF therapies.
[20]
 Based on findings from this study 
and existing literature, the authors would recommend use of anti-IL-1 agents first line as the 
most effective class of biologics for TRAPS. 
 
MKD/HIDS 
MKD/HIDS is the rarest of the three PFSs described in this study,
[5, 21, 22]
 and the collection of 
longitudinal records of 38 patients represents an important dataset. It has earliest onset (median 
of 0.5 years). The low awareness for this disease is reflected by the lack of diagnosis until 
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approximately 9 years of age, a 7-year delay in diagnosis from symptom onset, and a mean of 2.8 
physicians seen before referral to a recognised fever syndrome specialist. In addition, adult 
rheumatologists are even less familiar with these diseases and this can also lead to delays in 
diagnosis. A clear diagnostic guideline is therefore a critical need.  
It is noted that MKD/HIDS patients may have several phenotypes and single cases of early-onset 
inflammatory bowel disease and hepatosplenomegaly reported in this case review. Treatment has 
been focused on using anti-IL-1 (71% in first line), particularly anakinra, likely due to a 
prospective study showing favourable efficacy.
[23]
 Despite the majority of MKD/HIDS patients 
in this small retrospective study receiving anti-IL-1, there were no clear differences in response 
compared to anti-TNF, consistent with previous real world data suggesting there is no current 
evidence to support any particular order of biologic treatment options.
[6]
 A limitation of this 
study may be that no separate analysis could be performed for continuous versus intermittent use 
of biologicals. This may be especially important in MKD/HIDS where anakinra has been used to 
abort inflammatory attacks. Additionally, one potential source of bias is that differences 
observed between treatments could be due to differences in treating centres and their specific 
patient populations. We found there was a preference for one type of biologic agent in the 
majority of centres with only 25% of centres (4 of 16) using multiple agents in first line setting. 
As this study focussed on real world treatment patterns, we did not design this study to control 
for this potential bias. 
Conclusions 
This retrospective study highlights unmet needs for management of patients with FMF, TRAPS 
or MKD/HIDS. Referral patterns to specialised centres were assessed showing the impact of 
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disease rarity on non- or misdiagnosis and diagnostic delay. We note the need for greater 
awareness and the importance of improved diagnostics, particularly for the adult population. 
Biologic therapies have been widely adopted to treat otherwise inadequately controlled patients. 
This comparative assessment of real-world treatment response for current therapies will support 
further refinement of optimal treatment practice of these PFSs. A limitation of the study is the 
lack of independent measures to quantify treatment efficacy. Therefore, further prospective 
studies and randomised trials as well as robust measures of disease outcomes are needed to 
determine the most appropriate treatment options for these patients. 
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TABLES 
Table 1. Patient clinical characteristics at disease onset and diagnosis 
 FMF
[1] 
(n=49) 
TRAPS R92Q
[2] 
(n=6) 
TRAPS
[2] 
(n=41) 
MKD/HIDS
[2] 
(n=38) 
Age at disease onset (years), median (range) 2.0 (0.1 - 29.5) 10.4 (0.3 - 37.7) 7.4 (0.5 - 52.9) 0.5 (0.0 - 8.0) 
Age at disease diagnosis (years), median (range) 4.9 (0.5 - 31.0) 10.9 (2.0 - 40.7) 27.6 (0.6 - 76.3) 8.9 (0.8 - 46.0) 
Delay in diagnosis (years), median (range) 1.9 (0.0 - 21.7) 1.4 (0.3 - 11.7) 5.8 (0.0 - 75.8) 7.1 (0.5 - 45.5) 
Frequency of flares at disease onset (per annum), 
median (range), [N] 
  
Fever attacks
[3] 
26.0 (4.0 - 60.8) [43] 12.0 (1.0 - 36.5) [5] 6.0 (2.0 - 120.0) [29] 12.0 (4.0 - 36.5) [35] 
Arthritic attacks
[3] 
12.0 (6.0 - 52.0) [19] 12.0 (12.0 - 12.0) [1] 7.3 (3.0 - 12.0) [8] 12.5 (4.0 - 36.5) [8] 
Duration of flares at disease onset (days), median 
(range) 
  
Fever attacks
[3]
 3.0 (1.0 - 21.0) 3.0 (1.0 - 42.0) 14.0 (4.0 - 35.0) 5.0 (2.0 - 20.0) 
Arthritic attacks
[3] 
3.0 (1.5 - 7.0) 7.0 (7.0 - 7.0) 8.5 (5.0 - 28.0) 7.5 (4.0 - 20.0) 
Severe symptoms at disease onset,
[4]
 n (%)   
Fever 19 (39%) 3 (50%) 18 (44%) 33 (87%) 
Rash -- 2 (33%) 6 (15%) 5 (13%) 
Arthritis (excluding Arthralgia) 14 (29%) -- 2 (5%) 1 (3%) 
Serositis 26 (53%) 3 (50%) 10 (24%) 5 (13%) 
Elevated acute phase reactants (e.g. CRP and/or 
SAA) 
13 (27%) 3 (50%) 22 (54%) 30 (79%) 
Fatigue 6 (12%) 2 (33%) 12 (29%) 18 (47%) 
Painful lymph nodes -- -- 2 (5%) 18 (47%) 
GI upset
[5] 
20 (41%) 3 (50%) 22 (54%) 44 (116%)
[5]
 
Notes: 
[1] Countries presented in table for FMF cohort: France, Germany, Netherlands, United Kingdom, Israel and Turkey 
[2] Countries presented in table for TRAPS and MKD/HIDS cohorts: USA, France, Germany, Netherlands, United Kingdom, Israel and Turkey 
[3] Fever and arthritic attacks can occur simultaneously 
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[4] Severity characterised as response of Severe and Very Severe based on physician characterisation 
[5] Multiple options of GI upset could be selected including abdominal pain, loss of appetite, nausea/vomiting and diarrhoea 
  
Page 24 of 33
John Wiley & Sons, Inc.
Arthritis Care & Research
50
51
52
53
54
55
56
57
58
59
60
This article is protected by copyright. All rights reserved.
    
24 
 
Table 2. Referral patterns at time of presentation to specialist by patient age 
 FMF
[1] 
TRAPS R92Q
[2] 
TRAPS
[2] 
  MKD/HIDS
[2] 
Children
[3] 
Adults
[3] 
Children
[3]
 Adults
[3]
 Children
[3]
 Adults
[3]
 Children
[3]
 Adults
[3]
 
Number of patients, n (%) 36 (73%) 13 (27%) 4 (67%) 2 (33%) 17 (41%) 24 (59%) 25 (66%) 13 (34%) 
Number of physicians seen for PFS 
before diagnosis, n (%) 
  
[1-2] 30 (83%) 8 (62%) -- 1 (50%) 11 (65%) 7 (29%) 19 (76%) 1 (8%) 
[3-4] 5 (14%) 4 (31%) 3 (75%) -- 5 (29%) 11 (46%) 6 (24%) 7 (54%) 
[5-6] 1 (3%) 1 (8%) -- 1 (50%) 1 (6%) 6 (25%) -- 5 (38%) 
> 6 -- -- 1 (25%) -- -- -- -- -- 
Specialty of referring physician,
[4]
 n (%)   
General practitioner (GP) 7 (21%) 6 (46%) 1 (25%) -- 2 (12%) 3 (15%) 3 (13%) 2 (15%) 
Pediatricians
 
19 (58%) 2 (15%) 2 (50%) -- 10 (59%) -- 11 (48%) 1 (8%) 
Pediatric rheumatologists -- 1 (8%) -- -- 1 (6%) -- 2 (9%) -- 
Rheumatologists 5 (15%) 1 (8%) -- -- 3 (18%) 4 (20%) 1 (4%) 4 (31%) 
Other
[5]
 2 (6%) 3 (23%) 1 (25%) 2 (100%) 1 (6%) 13 (65%) 6 (26%) 6 (46%) 
Referring physician diagnosis,
[6]
 n (%)   
Correct diagnosis 11 (52%) 3 (75%) -- -- 1 (11%) 5 (28%) 3 (23%) -- 
Incorrect diagnosis   
Incorrect PFS -- -- -- -- 1 (11%) 1 (6%) 1 (8%) -- 
PFAPA -- -- -- -- 1 (11%) -- -- -- 
JIA 1 (5%) -- -- -- -- -- -- -- 
Rheumatoid arthritis (RA) -- -- -- -- -- 1 (6%) -- -- 
Auto-inflammatory disease not 
specified 
-- -- 1 (25%) -- -- 1 (6%) -- 3 (50%) 
Other
[7]
 5 (24%) -- -- -- 4 (44%)  4 (24%) 4 (31%) -- 
None 4 (19%) 1 (25%) 3 (75%) 2 (100%) 2 (22%) 5 (28%) 5 (38%) 3 (50%) 
Notes: 
[1] Countries presented in table for FMF cohort: France, Germany, Netherlands, United Kingdom, Israel and Turkey 
[2] Countries presented in table for TRAPS and MKD/HIDS cohorts: USA, France, Germany, Netherlands, United Kingdom, Israel and Turkey 
[3] Children refer to patients less than 18 years of age at time when first seen by specialist; adults were 18 years of age or older 
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[4] Referring physician was not indicated on 9 patient records 
[5] Other physicians include cardiologist, infectious disease specialist, immunologist, gastroenterologist, amyloidosis specialist, ENT, general 
surgeon, paediatric surgeon, nephrologist, neurologist, pulmonologist and internist 
[6] Referring physician diagnosis available in 79 patient records 
[7] Other diagnoses include polymyalgia rheumatica, acute rheumatic fever, chronic auto-inflammatory syndrome, Henoch-Schonlein purpura, 
immune deficiency, inflammatory bowel disease, periodic fever, recurrent idiopathic pericarditis, recurrent Kawasaki disease, septic arthritis, 
serositis, systemic vasculitis, "ununderstood" inflammation and urinary tract infection 
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Table 3. Summary of utilisation of biologic agents by line of therapy and disease 
 First Biologic Agent 
Patients who 
received 
biologics, n 
Anti-IL-1 Anti-TNF Anti-IL-6 Other 
anakinra canakinumab adalimumab etanercept tocilizumab 
interferon 
alpha 
FMF
[2]
 27 14 (52%) 8 (30%) 2 (7%) 2 (7%) -- 1 (4%) 
TRAPS R92Q
[3]
 6 2 (33%) -- -- 4 (67%) -- -- 
TRAPS
[3]
 37 15 (41%) 2 (5%) -- 20 (54%) -- -- 
MKD/HIDS
[3]
 31 21 (68%) 1 (3%) -- 8 (26%) 1 (3%) -- 
 Second Biologic Agent 
FMF
[2]
 11 6 (55%) 5 (45%) -- -- -- -- 
TRAPS R92Q
[3]
 -- -- -- -- -- -- -- 
TRAPS
[3]
 12 9 (75%) 2 (17%) 1 (8%) -- -- -- 
MKD/HIDS
[3]
 7 1 (14%) 3 (43%) -- 2 (29%) 1 (14%) -- 
 Third Biologic Agent 
FMF
[2]
 -- -- -- -- -- -- -- 
TRAPS R92Q
[3]
 -- -- -- -- -- -- -- 
TRAPS
[3]
 4 1 (25%) 2 (50%) -- -- 1 (25%) -- 
MKD/HIDS
[3] [4]
 2 1 (50%) -- -- -- 1 (50%) -- 
Notes: 
[1] Treatment patterns are represented by each patient's line of therapy as indicated in each patient's treatment flowchart 
[2] Countries presented in table for FMF cohort: France, Germany, Netherlands, United Kingdom, Israel and Turkey 
[3] Countries presented in table for TRAPS and MKD/HIDS cohorts: USA, France, Germany, Netherlands, United Kingdom, Israel and Turkey 
[4] One MKD/HIDS patient was on a fourth agent anti-IL-1 (canakinumab) 
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Table 4. Summary of complete response rates of biologic agents by disease
[1][2]
 
Disease Agent 
Overall First Agent Second Agent 
Patients 
Exposed, 
n (%) 
Duration 
(Months), 
Mean, 
Median 
(Range) 
Patients 
Exposed, 
n (%) 
Complete 
Clinical 
Response, 
n (%)
[3]
 
Complete 
Biochemical 
Response, n 
(%)
[3]
 
Functional 
Status 
Improved, 
n (%)
[4] 
Patients 
Exposed, 
n (%) 
Complete 
Clinical 
Response,  
n (%)
[3]
 
Complete 
Biochemical 
Response, 
n (%)
[3]
 
Functional 
Status 
Improved, n 
(%)
[4] 
FMF
[5]
 
Anti-IL-1 
33 (87%) 
9.7, 3.0 
(1.0 - 96.0) 
22 (82%) 7 (50%) 6 (43%) 10 (91%) 11 (100%) 1 (33%) 1 (33%) 1 (50%) 
Anti-TNF 
4 (11%) 
9.3, 8.0 
(3.0 - 18.0) 
4 (15%) 1 (25%) 1 (25%) 1 (33%) -- -- -- -- 
Interferon 
alpha 
1 (3%) 
17.0, 17.0 
(17.0 - 
17.0) 
1 (4%) -- -- -- -- -- -- -- 
TRAPS 
R92Q
[6]
 
Anti-IL-1 
2 (33%) 
18.0, 18.0 
(6.0 - 30.0) 
2 (33%) 1 (50%) 1 (50%) 1 (100%) -- -- -- -- 
Anti-TNF 
4 (67%) 
8.8, 6.0 
(3.0 - 20.0) 
4 (67%) 1 (25%) 1 (25%) 3 (75%) -- -- -- == 
 
TRAPS
[6]
 
Anti-IL-1 
31 (58%) 
19.8, 10.5 
(1.0 - 
108.0) 
17 (46%) 14 (93%)* 
15 
(100%)** 
12 (80%) 11 (92%) 4 (44%) 6 (67%) 6 (75%) 
Anti-TNF 
21 (40%) 
25.4, 14.0 
(1.0 - 84.0) 
20 (54%) 12 (60%)* 8 (40%)** 6 (43%) 1 (8%) -- -- 1 (100%) 
Anti-IL-6 
1 (2%) 
16.0, 16.0 
(16.0 - 
16.0) 
-- -- -- -- -- -- -- -- 
 
MKD/HIDS
[6]
 
Anti-IL-1 
28 (68%) 
19.3, 17.0 
(0.2 - 64.0) 
22 (71%) 11 (52%) 9 (43%) 13 (81%) 4 (57%) -- -- -- 
Anti-TNF 
10 (24%) 
29.2, 14.5 
(2.0 - 94.0) 
8 (26%) 7 (88%) 6 (75%) 7 (100%) 2 (29%) -- -- 0 (0%) 
Anti-IL-6 
3 (7%) 
6.0, 3.0 
(3.0 - 12.0) 
1 (3%) 1 (100%) 1 (100%) 1 (100%) 1 (14%) -- -- -- 
Page 28 of 33
John Wiley & Sons, Inc.
Arthritis Care & Research
This article is protected by copyright. All rights reserved.
    
28 
 
Notes: 
[1] IL-1 agents: anakinra and canakinumab; anti-TNF agents: adalimumab and etanercept; and IL-6 agents: tocilizumab 
[2] Clinical and biochemical response was defined based on the best response across each course of treatment; complete clinical response was 
defined as no disease-associated symptoms; complete biochemical response was defined as normal levels of CRP / SAA (median <10mg/l) 
[3] Canakinumab response data was not collected as per exclusion criteria 
[4] Functional status improvement rated at 1-5 scale at end of treatment or last follow up by the treating physician. 1 represents ‘minor 
improvement’ to 5 ‘marketed improvement’. Analysis of 4s and 5s for known scores only.  
[5] Countries presented in table for FMF cohort: France, Germany, Netherlands, United Kingdom, Israel and Turkey 
[6] Countries presented in table for TRAPS and MKD/HIDS cohorts: USA, France, Germany, Netherlands, United Kingdom, Israel and Turkey 
* Difference in clinical response for anakinra and anti-TNF agents was statistically significant in TRAPS patients (p = 0.03) 
** Difference in biochemical response for anakinra and anti-TNF agents was statistically significant in TRAPS patients (p < 0.01) 
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